Federal Ministry of Health

Similar documents
Overview: TB Case Management and Contact Investigation

GUIDE: Reporting Template_Tuberculosis

WHO/HTM/TB/ Task analysis. The basis for development of training in management of tuberculosis

MONITORING AND EVALUATION PLAN

Management of patients with TB/HIV Gunta Kirvelaite

Country experience on engaging large hospitals - INDIA

Directly Observed Therapy and Case Studies Bridget Konz, RN September 28, 2011

Introducing New TB Medicines and Regimens: Is Success Driven by Systems? Chinwe Owunna Antonia Kwiecien Dumebi Mordi

Measurement of TB Indicators using e-tb Manager (TB Patient Management Information System)

BIOSTATISTICS CASE STUDY 2: Tests of Association for Categorical Data STUDENT VERSION

Ambulatory Care Day 1 for Multidrug Resistant Tuberculosis

Changing the paradigm of Programmatic Management of Drug-resistant TB

MANAGING AND MONITORING THE TB PROGRAMME

Assessment of Knowledge on management of Pulmonary Tuberculosis under RNTCP among graduating Interns and Postgraduate students in RIMS Imphal.

Epidemiological review of TB disease in Sierra Leone

HOW TO MONITOR LEPROSY ELIMINATION IN YOUR WORKING AREA. World Health Organization

Republic of Indonesia

Strengthening and Aligning Diagnosis and Treatment of Drug Resistant TB in India

Programmatic Management of MDR-TB in China: Progress, Plan and Challenge

Utilization of QI approaches to improve TB/HIV treatment outcomes in Swaziland

Fundamentals of Nursing Case Management

New Jersey Administrative Code Department of Health and Senior Services Title 8, Chapter 57, Communicable Disease

Initiation and scale-up of MDR-TB care in Ethiopia

Financial impact of TB illness

Improving the estimates of childhood TB disease burden and assessing childhood TB activities at country level

902 KAR 20:200. Tuberculosis (TB) testing for residents in long-term care settings.

Universal Access to MD TB Program in Cambodia. ITM, Antwerp 08 December Sam Sophan Cambodian Health Committee (CHC)

IHF Training Manual for TB and MDR-TB Control for Hospital/Clinic/Health Facility Managers Executive Summary 2

Monitoring and Evaluation Plan for the National Tuberculosis Strategic Plan

Systematic Engagement of Hospitals Philippine Experience. Dr. Marl Mantala 8 th PPM Sub-group Meeting, 10 Nov. 2012, Kuala Lumpur

Strengthening institutional capacity for nursing training on HIV/AIDS & Tuberculosis (GFATM R7) KNOWLEDGE, ATTITUDE & PRACTICES OF NURSES TOWARDS TB

Executive summary. 1. Background and organization of the meeting

How Do We Define Adherence? Improving Adherence to TB Treatment. Broad View of Adherence. What is adherence?

Sex : Choose patient sex (male or female). 3.1

Communicable Disease Control Manual Chapter 4: Tuberculosis

Management of Drug-resistant Tuberculosis

FAST. A Tuberculosis Infection Control Strategy. cough

Directly Observed Therapy for Active TB Disease and Latent TB Infection

Frequently Asked Questions about TB Protocols at Duke Hospital and Clinics ( Revision)

El Paso Integrated Physicians Group. Overview

ARMENIA. October By: Askar Yedilbayev

Performance of RNTCP NTI Bulletin 2003, 39 / 3&4, 19-23

LEVELS AND METHODS OF PUBLIC FINANCING OF TB SERVICE IN ARMENIA

Engagement of Workplace in TB Care and Control in Bangladesh. Dr. Md. Nazrul Islam Program Manager NTP Bangladesh

Declaration. P. A. Oduor

Registry eform Data Entry Guidelines Version Apr 2014 Updated for eform on 20 Jun 2016

rglc/europe TEECHNICAL ASSISTANCE MISSION TO ROMANIA

Grant Aid Projects/Standard Indicator Reference (Health)

Practical Aspects of TB Infection Control

Dyah Erti Mustikawati

FEDERAL MINISTRY OF HEALTH

Public Private Mix sub group meeting 23 October, 2011 Scale up PPM in Myanmar

5. returning the medication container to proper secured storage; and

WHO REPORT ON A JOINT REVIEW OF TUBERCULOSIS IN UKRAINE December 1999 REGIONAL OFFICE FOR EUROPE SCHERFIGSVEJ 8 DK 2100 COPENHAGEN Ø DENMARK

Momentum on Child TB: South East Asia (SEA)

Late-Breaker Abstract Session Submission Guidelines Deadline: Online submission 25 June 3 August 2018

MEASURE DHS SERVICE PROVISION ASSESSMENT SURVEY HEALTH WORKER INTERVIEW

Extensive Review of TB Prevention, Care and Control Services in

COATS Coordinating Center Memo #3

MONITORING THE SAFETY OF ANTIRETROVIRALS IN SOUTH AFRICA

Tuberculosis as an Occupational Disease. Molebogeng Malotle

Administrative Without, TB control fails. TB Infection Control What s New? Early disease prevention Modern cough etiquette

WHO Regional Publications, Eastern Mediterranean Series. Tuberculosis control in complex emergencies

CureTB Binational Tuberculosis Referral Training

Strategic Evaluation of TB CARE SMS System in Cambodia. Allyson Drew. Duke Global Health Institute Duke University.

Support of vulnerable patients throughout TB treatment in the UK

DECENTRALISED CARE FOR DR-TB:

KNOWLEDGE, ATTITUDE AND PRACTICES OF HEALTHCARE WORKERS ABOUT PREVENTION AND CONTROL OF MULTIDRUG-RESISTANT

2012 TB Laboratory Specimen Referral, Reporting & Transportation for diagnosis and management of MDR TB (January to June 2012)

Predicting Death. Estimating the proportion of deaths that are unexpected. National End of Life Care Programme

Tuberculosis (TB) Procedure

Priority programmes and rural retention the example of TB. Karin Bergstrom Stop TB Department WHO, Geneva

Management of Patients with Known or Suspected Tuberculosis: Infection Control Issues IC/198/10

FEDERAL MINISTRY OF HEALTH DEPARTMENT OF PUBLIC HEALTH. National Tuberculosis and Leprosy Control Programme. A Tuberculosis Infection Control Strategy

Essentials of Best Practice Recommendations for the Collection of Key Patient Data Attributes

TB Transmission Risk Reduction

Information and Guidance for the Deprivation of Liberty Safeguards (DoLS) Data Collection

Conclusion: Despite existing comprehensive feedback guidelines under RNTCP there was a lack of commitment in implementation of such guidelines.

THE UNITED REPUBLIC OF TANZANIA REPORT OF THE REVIEW OF THE NATIONAL TUBERCULOSIS AND LEPROSY PROGRAMME IN TANZANIA JUNE 2000

Strategy of TB laboratories for TB Control Program in Developing Countries

PARTNERSHIP FOR HIV FREE SURVIVAL HEALTH FACILITY COACHING GUIDE: SECOND VISIT (JUNE 2013) BRIEFLY INTRODUCE ASSIST PROJECT AND TEAM

2/8/2017 TB RISK ASSESSMENT OVERVIEW. To identify adults with infectious tuberculosis (TB) to prevent from spreading TB HISTORY

Adherence with Evidence-based TB Standards and Guidelines in Selected Health Facilities in Kenya

COPYRIGHT International Hospital Federation

902 KAR 20:205. Tuberculosis (TB) testing for health care workers.

Assessment of the quality of directly observed treatment short-course of tuberculosis in Bahir Dar city administration, North West Ethiopia

Pulmonary Tuberculosis Policy

Infection control and Revised National TB Control Programme

Review of the National Tuberculosis Programme in the Republic of Moldova

PPM PMDT LINKAGE A TOOLKIT

TUBERCULOSIS CONTROL RESEARCH MATRIX

Infection Prevention and Control Management of Pulmonary Tuberculosis Policy

Infection Control Care Plan for a patient with confirmed/ suspected Active Pulmonary Tuberculosis. Patient Demographic / Label

Prevention and Care- Role of Pharmacists. Prafull Sheth, FIP Vice President

Health Cluster Coordination Meeting. Friday December 4, 2015, Kiev

RITAZAREM CRF Completion Guidelines

The National Health Insurance Program Benefit Packages

Tuberculosis. Leader s Guide

Education Specialist Credential Program Application Full or Part Time. Student Information. Program Information. Field Placement (EHD 178)

Capture and Record Vital Signs Configuration Guide

Transcription:

Federal Ministry of Health MDR TB Follow up Register

INSTRUCTION FOR MDR TB REGISTRATION AT TREATMENT FOLLOW UP HEALTH FACILITIES SN Variable Description 1 MDR TB reg. Number Write a new unique patient identification number assigned by treatment initiating center. The MDRTB unique number is assigned as: Region/Type of facility/facility code/five digit serial number with DR prefix. For instance, If a patient is started on SLD treatment at St peter hospital and is the 22nd patient to be put on SLD at the center. His/her unique MDR number will be: 14/08/020/DR00022 Refering Health facility 2 Patient Name & Address Sex 3 Age 4 Contact person name & address Registration group 5 Site Resistance type (6,45) weight monitoring Write name of the health facility initiating the MDR TB treatment Upper space: Write patient name, father and grandfather name Lower space: Full address of the patient including telephone Number Enter M= Male and F= Female Enter age of patient as indicated in MDR TB treatment card Upper space: Write contact person name, father and grandfather name Lower space:full address of the contact person including telephone Number Upper space:there are seven possible options to choose. Select only one and enter the code as follow 1. New 2. Relapse 3. After default 4. Failure of new regimen 5. After failure of retreatment 6. Transfer in 7. Other Middle space:enter the site of TB: Pul for pulmonary and EP for extra-pulmonary NB: Patients with both pulmonary and extra pulmonary TB should be classified as a case of pulmonary TB. Lower Space: Write M for MDR; X for XDR; R for Mono-resistant; and P for Poly-resistant Write weight of the patient in space provided at monthly base; copy all weight monitored at the treatment center from the treatment card of the partient in to the registartion and continue montoring of patient weight at your facility for intensive & continuation phases. 7 Intensive Phase:Drugs Enter each drug abbreviations being used in the intensive phase 8 Intensive Phase:Dose Enter the dose of each drug during the intensive phase. 9 Treatment started write the date treatment started as(ec); Day/Month/Year (10,11) 12 (13-42) Intensive Phase: Smear & culture result Write the month Treatment monitoring: Intensive phase Record all smear and culture results specific to the month on treatment. If more than one smear or culture done in a month, enter the most recent result. Use the following abbreivation in the space provided: Enter P for positive result usingred pen; N for negative results and U for results not available/not done Write the name of the month(eg:- Tikimit, Hidar..) for each month of intensive treatment until the patient finished his/her treatment. This part is used to record daily drugs administered/taken by the patient during the intensive phase; one box is checked for each day the treatment administered. For instance if the patient has morning and evening doses, divide the box in to two part and use in the upper portion to check for morning doses and the lower portion for evening does. Write 3 for directly observed; 2 for not observed; 1 drug not taken/missed does. 43 Continuation Phase:Drugs Enter the initial of each MDR TB regimen being used by individual patient in the continuation phase. 44 (46,47) Continuation Phase:Dose Continuation Phase: Smear & culture result Enter dose in milligram of each MDR TB regimen being used by the individual patient during in the continuation phase. Record all smear and culture results specific to the month on treatment. If more than one smear or culture done in a month, enter the most recent result. Use the following abbreivation in the space provided: Enter P for positive result usingred pen; N for negative results and U for results not available/not done

(48-59) Treatment monitoring: continuation phase (60-66) Treatment outcome Enter the days in the rows for the monthly column when the patient attended for treatment montoring during the continuation period of treatment. calander. Cured: Patients who have completed treatment according to programme protocol and have at least five consecutive negative cultures from samples collected at least 30 days apart in the final 12 months of treatment. Clinicians may mark a patient as cured if only one of the cultures is positive, but it is followed by three consecutive negative cultures and there is no concomitant clinical evidence of deterioration. Treatment completed: Patients who have completed treatment but do not meet the definition of cured, eg who do not have at least five cultures taken in the final twelve months. Failed: Patients for whom two or more of the final five cultures are positive, or if any one of the final three cultures is positive, or for whom treatment has been terminated early. Died: A patient who dies for any reason during the course of TB treatment. Default: A patient who has been on treatment for at least four weeks and whose treatment was interrupted for eight or more consecutive weeks. Transfer out: A patient who has been transferred to another recording and reporting unit and whose final treatment outcome is unknown. No outcome assigned: a patient in treatment program whose final outcome cannot be determined as he/she is still on treatment at the end of reporting period. (97-69) TB/HIV activities (70,71) Adverse effect Enter Testing results if the patient tested for HIV. Enter R in red pen if test is reactive; NR in normal color of pen if test is not reactive or I in normal color of pen if test is indeterminate. Upper Space: Enter the initial of suspect MDR TB drug Lower Space: Write the side effect observed and the action taken for the adverse in the next column 72 Remarks Write any remarks relate to patient care, treatment,outcome, etc...

Multidrug Resistance TB Follow up Register MDR TB Reg. Number Refering Facility Name Name of patient Address of Patient (Woreda, kebele, H.No. telephone No.) Sex (M/F) Name of contact Person Address of contact person (Woreda, kebele, H.No. Telephone) Registration Gruop (1,2,3,4,5,6,7) Type Pul/EP Age Drugs Dose Resistance type (M(X)DR,poly/Monore sistant) Monthly Weight monitoring Intensive phase Treatment started Smear Culture Write the Month 1 2 3 4 5 6 7 8 9 10 11 12 13 Days: Intensive Phase treatment Monitroing chart 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) Foot Notes: Drug Abbreviations First line drugs: H= Isoniazid R=Rifampicin E=Ethambutol Z= Pyrazinamide S = Streptomycin Th= Thioacetazone Second line drugs : Am= Amikacin Cm=Capreomycin Ofx=Ofloxacin Lfx=Levofloxacin Mtx=Moxifloxacin Pto=protionamide Eto=Ethionamide Cs=Cycloserine PAS=Paminosalicylic acide Registration Group 1. New 2. Relapse 3. After default 4. Failure of new regimen 5. After failure of retreatment 6. Transfer in (from another MDR TB treatment site) 7. Other

Facility Name Year Continuation phase Weekly attendance: Continuation Phase Treatment Monitroing Chart Write the date of the treatment out come in appropriate column TB/HIV activities Adverse effect Drug Dose Weight monitoring Smear Culture Hamle Nehase Meskerem Tikimt Hidar Tahisas Tir Yekatit Megabit Miaza Ginbot Sene Cured Treatment Completed Died Failure Defaulted Transferred Out No outcome assigned Test (R/NR) CPT (Y/N ) ART(Y/N ) Drug Started date Started date Adverse effect Action taken Remarks (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) (66) (67) (68) (69) (70) (71) (72)